Pyxis Oncology (PYXS) Net Income towards Common Stockholders (2020 - 2025)

Pyxis Oncology (PYXS) has 6 years of Net Income towards Common Stockholders data on file, last reported at -$18.4 million in Q4 2025.

• On a quarterly basis, Net Income towards Common Stockholders rose 48.3% year-over-year to -$18.4 million in Q4 2025; TTM through Dec 2025 was -$81.3 million, a 5.25% increase from a year earlier, with the FY2025 full-year figure at -$79.6 million, down 2.96% from the prior year.
• Net Income towards Common Stockholders for Q4 2025 stood at -$18.4 million, up from -$22.0 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for PYXS reached as high as -$5.9 million in Q2 2021 and fell as low as -$46.4 million in Q3 2021.
• Historically, Net Income towards Common Stockholders has averaged -$26.0 million across 5 years, with a median of -$23.3 million in 2023.
• Across the five-year window, Net Income towards Common Stockholders plunged 1353.15% in 2021 and jumped 54.22% in 2024, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$32.8 million in 2021, then retreated by 8.01% to -$35.5 million in 2022, then jumped by 50.45% to -$17.6 million in 2023, then slumped by 102.42% to -$35.6 million in 2024, then jumped by 48.3% to -$18.4 million in 2025.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$18.4 million in Q4 2025, -$22.0 million in Q3 2025, and -$18.4 million in Q2 2025.